Current and future antifungal therapy: New targets for antifungal therapy
Open accessAbstract
Invasive fungal infections will continue to cause major complications in immunocompromized patients. At the moment, the expansion of antifungal drug research has occurred because there is a critical need for new antifungal agents to treat these life-threatening invasive fungal infections. The overview of the development of antifungal therapy which is provided here demonstrates the increased interest in this very special area of infectious diseases. Although we now have some newer and less toxic antifungal agents that are currently available for clinical use, their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not very good. Intense efforts in antifungal drug discovery are urgently needed to develop more promising and effective antifungal agents for use in the clinical arena.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fluconazole is the azole drug most widely used for the treatment of Candida infections, and its utility is attributed to high bioavailability, high water solubility, and low affinity to plasma proteins.
“Fluconazole is the azole drug most widely used for the treatment of Candida infections. Its utility is attributed to its high bioavailability, high water solubility, and low affinity to plasma proteins [21].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [21]
The citation lists haven’t been fetched yet
References 9 · Cited by 97
- Authors
- Andriole, V. T.
- Affiliations
- Yale University (US)
- Corresponding author
- Andriole, Vincent T
- Venue
- International Journal of Antimicrobial Agents
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 16
- Issue
- 3
- Pages
- 317-321
- ISSN
- 0924-8579 (ISSN-L)
- OpenAlex
- W1977059679
- Cited by
- 97
- References
- 9
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 5 · 2022: 6 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 6 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 4
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Antimicrobial Agents (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- antifungal agents, antifungal drug discovery, invasive fungal infections, immunocompromised patients, aspergillosis, fusariosis, antifungal drug targets, clinical efficacy
- MeSH terms
- Antifungal Agents, Forecasting, Humans, Mycoses, Nucleosides, Polyenes, Drug Design, Immunocompromised Host
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
